Translate Bio Inc (NASDAQ:TBIO) Expected to Announce Quarterly Sales of $2.18 Million

Brokerages expect Translate Bio Inc (NASDAQ:TBIO) to post sales of $2.18 million for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Translate Bio’s earnings, with the highest sales estimate coming in at $3.70 million and the lowest estimate coming in at $1.20 million. Translate Bio reported sales of $1.17 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 86.3%. The firm is expected to report its next earnings report on Wednesday, July 29th.

On average, analysts expect that Translate Bio will report full year sales of $10.91 million for the current financial year, with estimates ranging from $8.73 million to $14.60 million. For the next financial year, analysts forecast that the company will post sales of $10.33 million, with estimates ranging from $6.00 million to $14.60 million. Zacks’ sales calculations are an average based on a survey of research analysts that cover Translate Bio.

Translate Bio (NASDAQ:TBIO) last issued its earnings results on Thursday, March 12th. The company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.12). The business had revenue of $3.89 million during the quarter, compared to analyst estimates of $3.06 million. Translate Bio had a negative net margin of 859.22% and a negative return on equity of 63.61%.

A number of brokerages have weighed in on TBIO. Zacks Investment Research raised Translate Bio from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a report on Friday, May 15th. TheStreet raised Translate Bio from a “d” rating to a “c-” rating in a report on Monday, May 18th. Finally, ValuEngine raised Translate Bio from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd. Six research analysts have rated the stock with a buy rating, Translate Bio currently has an average rating of “Buy” and a consensus target price of $20.20.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. First Allied Advisory Services Inc. increased its stake in shares of Translate Bio by 46.2% during the fourth quarter. First Allied Advisory Services Inc. now owns 19,000 shares of the company’s stock valued at $155,000 after purchasing an additional 6,000 shares in the last quarter. State Street Corp grew its holdings in shares of Translate Bio by 12.7% during the third quarter. State Street Corp now owns 563,057 shares of the company’s stock valued at $5,580,000 after buying an additional 63,425 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Translate Bio by 7.4% during the fourth quarter. Geode Capital Management LLC now owns 546,581 shares of the company’s stock valued at $4,449,000 after buying an additional 37,577 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Translate Bio during the fourth quarter valued at approximately $129,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of Translate Bio by 24.6% during the fourth quarter. Bank of New York Mellon Corp now owns 127,775 shares of the company’s stock valued at $1,040,000 after buying an additional 25,211 shares during the last quarter. 82.63% of the stock is currently owned by institutional investors.

Shares of TBIO stock opened at $18.98 on Friday. The stock’s fifty day moving average price is $12.63 and its two-hundred day moving average price is $9.62. The company has a market cap of $1.21 billion, a PE ratio of -11.16 and a beta of 0.25. Translate Bio has a fifty-two week low of $6.80 and a fifty-two week high of $21.95. The company has a debt-to-equity ratio of 0.08, a quick ratio of 4.12 and a current ratio of 4.12.

Translate Bio Company Profile

Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.

Featured Article: Average Daily Trade Volume – ADTV

Get a free copy of the Zacks research report on Translate Bio (TBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Translate Bio (NASDAQ:TBIO)

Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply